Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 5, 2002, Pages 867-873

  Juhan Vague, I ^a   Morange, P E ^a   Aubert, H ^a   Henry, M ^a   Aillaud, M F ^a   Alessi, M C ^a   Samnegard A ^b   Hawe, E ^c   Yudkin, J ^c   Margaglione, M ^d   Di Minno, G ^d   Hamsten, A ^b   Humphries, S E ^c   Boquist, S ^e   Ericsson, C G ^e   Lundman, P ^e   Samnegard, A ^e   Silveira, A ^e   Tornvall, P ^e   Mohamed Ali, V ^e   Holmes, A ^e   Ambrosi, P ^e   Canavy, I ^e   Paganelli, F ^e   Didelot, R ^e   Ansaldi, J ^e   Billerey, M ^e   Cimino, D ^e   Dello Iacono, N ^e   Cimino, A ^e   Gaeta, G ^e   Blasich, C ^e   Pucciarelli, G ^e   Ahn Luong, L ^e   Van Hinsbergh, V ^e   Kooistra, T ^e   Tremoli, E ^e   Banfi, C ^e   Mussoni, L ^e   more..

^a TIMONE HOSPITAL   (France)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e NONE

Author keywords

Fibrinolysis; Genetic polymorphisms; Myocardial infarction; Thrombin activatable fibrinolysis inhibitors

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY RISK; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FRANCE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEART INFARCTION; HETEROZYGOTE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SWEDEN; UNITED KINGDOM;

EID: 0036091541     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000015445.22243.F4     Document Type: Article

References (36)

1. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor
2. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma
3. Purification and characterization of a new arginine carboxypeptidase in human serum
4. Plasma carboxypeptidases as regulators of the plasminogen system
5. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
6. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
7. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor
8. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: In vivo evidence for a role of factor XI as an antifibrinolytic factor
9. A novel approach to arterial thrombolysis
10. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and haemostasis
11. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model
12. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
13. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease
14. Plasma TAFI antigen variations in healthy subjects
15. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors
16. Characterization of the gene encoding human TAFI (thrombin-activatable fibrinolysis inhibitor; plasma procarboxypeptidase B)
17. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: Evidence that plasma antigen levels are strongly genetically controlled
18. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms
19. Lp(a) levels are higher in myocardial infarction survivors than healthy subjects from the south but not the north of Europe (HIFMECH Study)
20. A simple salting out procedure for extracting DNA from human nucleated cells
21. Nonuniform recombination within the human beta-globin gene cluster
22. PAI-I obesity, insulin resistance and risk of cardiovascular events
23. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-I activity and antigen plasma concentrations: A family study with part of the Stanislas Cohort
24. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: Relationship with plasma TAFI levels and risk of venous thrombosis
25. Carboxypeptidase U: A plasma carboxypeptidase with high affinity for plasminogen
26. Purification and characterization of a non-activatable form of TAFI in complex with fibrinogen
27. Assay of carboxypeptidase N activity in serum by liquid-chromatographic determination of hippuric acid
28. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels
29. Two naturally occurring variants of TAFI (Thr 325 and Ile 325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme
30. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway
31. Human procarboxypeptidase U, or thrombinactivatable fibrinolysis inhibitor, is a substrate for transglutaminases: Evidence for transglutaminase-catalyzed cross-linking to fibrin
32. Plasminogen and tissue plasminogen activator interact with antithrombin lII
33. Pro-carboxypeptidase R cleaves bradykinin following activation
34. Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy
35. Activation and characterization of procarboxypeptidase B from human plasma
36. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms